Disclosed is a vaccine adjuvant including at least one inverse microlatex, the inverse microlatex including at least one oil, at least one surfactant, at least one polymer such as, for example, a polyacrylate that is totally or partially neutralized in the form of alkali metal salts or ammonium salt, the vaccine adjuvant being entirely sterilizable by filtration or by passing through the heat of an autoclave and emulsifiable in one step with the aqueous phase including only a vaccine antigen.

Provided is an African swine fever virus chimeric protein. The chimeric protein comprises: (1) an African swine fever virus p72 domain I; (2) an African swine fever virus p72 domain II; (3) an African swine fever virus p72 domain III; and (4) an African swine fever virus antigenic protein. By using African swine fever virus p72 protein as a skeleton, the chimeric protein provided in the present invention will exhibit antigenic epitopes of African swine fever virus antigenic proteins p54, p30, CD2v, and p12, achieve a good immune effect, and can produce significant humoral and cell-mediated immune response.

Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioactive agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject. The presently disclosed subject matter further relates to a method of preparing the composition.

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the shedding of Lawsonia intracellularis bacteria associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.

The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.

The present invention relates to vaccine compositions comprising attenuated strain of Tilapia Lake Virus (TiLV) for protecting tilapia fish against infection by (TiLV). The invention also relates to methods for using the vaccines to protect tilapines from TiLV-induced disease.

Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines.

Isolated porcine epidemic diarrhea virus (PEDV) deposited under ATCC Accession No. PTA-121847, and attenuated strains generated by serial passage in culture of the deposited strain. Immunogenic compositions for reducing the incidence or severity of clinical symptoms from PEDV infection, and methods of making and using the same.